Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity
about
Onto better TRAILs for cancer treatmentEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsPrinciples of antibody-mediated TNF receptor activationCaspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcomaEnhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal ToxicityMiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation.Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directionsDeath ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.Therapeutic targeting of CD70 and CD27.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5.Strategic internal covalent cross-linking of TNF produces a stable TNF trimer with improved TNFR2 signaling.Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.Crystal structure of CD27 in complex with a neutralizing noncompeting antibody.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.The activity of TRAF RING homo- and heterodimers is regulated by zinc finger 1.Structural principles of tumor necrosis factor superfamily signaling.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
P2860
Q26768160-40338FC3-F1A4-4606-B596-08B8167927FBQ26768267-3BF9A156-0DAD-4184-8A81-BD98B9E4E1D5Q26796270-C28E5A63-C761-4E45-B583-AF054ECDD757Q27853200-11471500-82C3-429A-80F5-75D3C0444C64Q35590091-C2BDB806-34BC-44F3-83B8-E75B238AAD9CQ35931441-52E06737-0A2A-406A-B8D2-D95C7005FE59Q36992161-5EDFBF08-C76B-45D8-A09C-F20F2C3796FAQ37114025-766AF4DB-4C8F-452D-97E0-EA82B0B15DD0Q37211515-35FD82D6-7132-4860-B22C-B1B28769BB5CQ37295313-81391DAA-7C53-434C-9F6B-D564153BEAE6Q37330410-B4A3DFED-0310-4D82-9454-679279291E49Q37412514-8D711BEA-BE93-49C5-9E37-40EE728BBD39Q37492231-AFE01CA2-0092-4585-AAE2-D879D73D40A3Q37702210-32DE7F29-AC0D-45AD-B4C2-8C97A66E2757Q38340808-BD74A45C-FB2F-4AE2-9F82-7CB7A855BF78Q38575137-7AC5C2B8-BCD7-42B2-B542-4C8C7EDAB689Q38681598-1F6A1F27-3302-4D84-9DEF-984B82C40FC3Q38749841-EEBEB96A-06AB-487C-8043-AFBDCE007399Q38770814-6DCA01C1-D43C-4929-B7EA-EBD37AE95D8CQ38811508-787EAA84-22EB-4E0C-BEF7-FEF8E9078750Q38823727-25EE3D73-DDAE-4870-8CAC-92263B2BBE9FQ38885494-3602701A-6861-425C-B90A-10F5FE20E60AQ38888391-CA1D6FCC-7D4C-4CF2-A289-D65CEA24D52DQ39908453-77DED81D-BB1C-46DE-9FA0-46DC60D843CEQ41057098-29F46623-589C-4A43-83D8-F77C38C9402CQ41242816-0EE8AD47-7668-4810-AD30-4A4FE201B6DDQ42289647-5CFBAE22-EE66-4DAA-B58C-24F5C3CE469FQ42558833-7F1636B0-05D0-4D2F-B8C5-6B1A4E079577Q42709967-24192DCB-0750-4C7B-B133-E3627DB19446Q45903630-F2AA0232-C05C-4AC9-8AF2-632277968BA0Q47111337-23BD8BA3-96A0-4951-965A-12DF08DE704AQ48319204-D28F23D7-3CEF-4599-B545-60D33F040398Q51760860-1ABB5BCD-D8A1-4C78-86AC-FD479EF134A7Q52342639-50B87CD0-AD0A-4F9C-8AD7-A4A0949DF495Q52369544-17218265-A5D1-4147-B166-231C0094B91BQ52579567-4DD1C2FD-9D97-41F3-B137-87AD68638AF7Q52715823-8BA4B717-6B97-49E7-AFD1-A783DC7816F5Q58586476-876BF33A-FD1E-49DA-A7CB-DD429308509F
P2860
Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@ast
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en-gb
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@nl
type
label
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@ast
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en-gb
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@nl
prefLabel
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@ast
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en-gb
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@nl
P2093
P3181
P1433
P1476
Apo2L/TRAIL and the death rece ...... stering and antitumor activity
@en
P2093
Alexander M Long
Daniel G Branstetter
Heather Douangpanya
Ian N Foltz
Jason W O'Neill
Jennifer J Kordich
John M Rossi
Jonathan D Graves
Julia Piasecki
Pamela M Holland
P304
P3181
P356
10.1016/J.CCR.2014.04.028
P407
P577
2014-08-11T00:00:00Z